EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022

Patricia Mae G. Santos, Lillian A. Boe, Kawther Al Ksir, Ticiana Leal, Daniel R. Gomez, Ravi B. Parikh

Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)

DOI: 10.6004/jnccn.2026.7043 ↗
AbstractBibliografische Angaben

Abstract

Background: Nearly half of patients with advanced non–small cell lung cancer (aNSCLC) have actionable mutations that can be detected through broad-based genomic sequencing (BGS) or focused biomarker testing (FBT). Although national guidelines advocate for early BGS, its impact on survival in the era of targeted therapy remains unclear. This study evaluates whether BGS is associated with improved progression-free survival (PFS) and overall survival (OS) compared with FBT. Patients and Methods: This retrospective cohort study used electronic health record data from the Flatiron Health Research Database (2016–2022), which includes data from approximately 280 US academic and community oncology clinics. Adults (age ≥18 years) with stage IIIB–IV NSCLC who received at least one line of systemic therapy were included. Patients were categorized based on receipt of BGS or FBT

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →